![James McArthur](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
James McArthur
Directeur Général chez
PEPGEN INC.
Fortune : 188 666 $ au 31/08/2026
Profil
James Gregg McArthur was the founder of Adheron Therapeutics, Inc. founded in 2006, serving as Chief Scientific Officer from 2006 to 2012.
Dr. McArthur is the founder of Cydan LLC founded in 2012, serving as President-Research & Development since 2012.
Dr. McArthur is the founder of Vtesse, Inc. founded in 2015.
Dr. McArthur was the founder of Imara, Inc. founded in 2016, serving as Director from 2018 to 2020.
Dr. McArthur was the founder of Tiburio Therapeutics, Inc. founded in 2019, serving as Secretary & Director.
Dr. McArthur is also the founder of Cydan II, Inc...
Dr. McArthur is President, CEO & Executive Director at PepGen Ltd. since 2021.
Dr. McArthur is President, Chief Executive Officer & Director at PepGen Inc. Dr. McArthur is Director at The Friedreich's Ataxia Research Alliance.
Dr. McArthur was Director at NightstaRx Ltd. Dr. McArthur was Independent Non-Executive Director at Nightstar Therapeutics Ltd. from 2016 to 2019.
Dr. McArthur was Director at T-Cure Bioscience, Inc. in 2020.
Dr. McArthur was Vice President-Research at Cell Genesys, Inc. from 1996 to 2002.
Dr. McArthur was Vice President-Research & Preclinical Development at Phylogix, Inc. Dr. McArthur completed undergraduate and doctorate degrees at McGill University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PEPGEN INC. 0,09 % | 31/03/2026 | 63 099 ( 0,09 % ) | 188 666 $ | 31/08/2026 |
Postes actifs de James McArthur
| Sociétés | Poste | Début |
|---|---|---|
| PEPGEN INC. | Directeur Général | 06/08/2021 |
Cydan LLC
 Cydan LLC Medical DistributorsDistribution Services Operates as an orphan drug accelerator that identifies and de-risks programs | Fondateur | 01/01/2012 |
The Friedreich's Ataxia Research Alliance
 The Friedreich's Ataxia Research Alliance Information Technology ServicesTechnology Services Provides patient registry services | Directeur/Membre du Conseil | - |
Anciens postes connus de James McArthur
| Sociétés | Poste | Fin |
|---|---|---|
T-Cure Bioscience, Inc.
 T-Cure Bioscience, Inc. BiotechnologyHealth Technology Develops clinical-stage T cell receptor therapies for the treatment of cancer | Directeur/Membre du Conseil | 01/09/2020 |
| IMARA | Fondateur | 22/04/2020 |
| NIGHTSTAR THERAPEUTICS PLC | Directeur/Membre du Conseil | 07/06/2019 |
Adheron Therapeutics, Inc.
 Adheron Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company | Fondateur | 01/09/2012 |
Phylogix, Inc.
 Phylogix, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic drugs | Directeur Technique/Scientifique/R&D | 02/09/2009 |
Formation de James McArthur
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
67
Relations au 1er degré
15
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 15 |
|---|---|
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Develops human disease therapies based on innovative gene modification technologies | Health Technology |
Adheron Therapeutics, Inc.
Adheron Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company | Health Technology |
McGill University
 McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Phylogix, Inc.
Phylogix, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic drugs | Health Technology |
Cydan II, Inc.
 Cydan II, Inc. Pharmaceuticals: GenericHealth Technology Develops and commercializes drugs | Health Technology |
Cydan LLC
Cydan LLC Medical DistributorsDistribution Services Operates as an orphan drug accelerator that identifies and de-risks programs | Distribution Services |
The Friedreich's Ataxia Research Alliance
The Friedreich's Ataxia Research Alliance Information Technology ServicesTechnology Services Provides patient registry services | Technology Services |
Vtesse, Inc.
 Vtesse, Inc. BiotechnologyHealth Technology Engages in pre-clinical and clinical studies and develops drugs for patients suffering from diseases | Health Technology |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services development of therapies for retinal dystrophies | Health Services |
Imara, Inc.
 Imara, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes novel therapeutics for patients with sickle cell disease | Health Technology |
Nightstar Therapeutics Ltd.
 Nightstar Therapeutics Ltd. BiotechnologyHealth Technology Operates as a gene therapy company that develops novel treatments for patients suffering from inherited retinal diseases | Health Technology |
Pepgen Ltd.
 Pepgen Ltd. Packaged SoftwareTechnology Services Develops peptide drug delivery platform technology | Technology Services |
Tiburio Therapeutics, Inc.
 Tiburio Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnological research and developmental services | Health Technology |
T-Cure Bioscience, Inc.
T-Cure Bioscience, Inc. BiotechnologyHealth Technology Develops clinical-stage T cell receptor therapies for the treatment of cancer | Health Technology |
PepGen Inc.
 PepGen Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company which develops oligonucleotide therapeutics for treatment of severe neuromuscular and neurologic diseases | Health Technology |
